Literature DB >> 16471148

Trends and geographic inequalities in the prevalence of Down syndrome in Europe, 1980-1999.

H Dolk1, M Loane, E Garne, H De Walle, A Queisser-Luft, C De Vigan, M C Addor, B Gener, M Haeusler, H Jordan, D Tucker, C Stoll, M Feijoo, D Lillis, F Bianchi.   

Abstract

BACKGROUND: EUROCAT is a network of population-based registries for the epidemiologic surveillance of congenital anomalies covering approximately one quarter of births in the European Union. Down syndrome constitutes approximately 8% of cases of registered congenital anomaly in Europe, with over 7000 affected pregnancies in the 15 current member states of the European Union each year. In this paper, we aim to examine trends in the live birth prevalence of Down syndrome in Europe in the light of trends in maternal age and in prenatal diagnosis.
METHODS: Descriptive analysis of data from 24 EUROCAT registries, covering 8.3 million births 1980-99. Cases include live births, stillbirths and terminations of pregnancy following prenatal diagnosis.
RESULTS: Since 1980, the proportion of births to mothers of 35 years of age and over has risen quite dramatically from 8 to 14% for the European Union as a whole, with steeper rises in some regions. By 1995-1999, the proportion of "older" mothers varied between regions from 10% to 25%, and the total prevalence (including terminations of pregnancy) of Down syndrome varied from 1 to 3 per 1000 births. Some European regions have shown a more than twofold increase in total prevalence of Down syndrome since 1980. The proportion of cases of Down syndrome which were prenatally diagnosed followed by termination of pregnancy in 1995-1999 varied from 0% in the three regions of Ireland and Malta where termination of pregnancy is illegal, to less than 50% in 14 further regions, to 77% in Paris. The extent to which terminations of pregnancy were concen trated among older mothers varied between regions. The live birth prevalence has since 1980 increasingly diverged from the rising total prevalence, in some areas remaining approximately stable, in others decreasing over time.
CONCLUSION: The rise in average maternal age in Europe has brought with it an increase in the number of pregnancies affected by Down syndrome. The widespread practice of prenatal screening and termination of pregnancy has in most of the regions covered by EUROCAT counteracted the effect of maternal age in its effect on live birth prevalence. Under the joint influences of maternal age and prenatal screening the pattern of geographic inequalities in Down syndrome live birth prevalence in Europe has also been changed.

Entities:  

Mesh:

Year:  2005        PMID: 16471148

Source DB:  PubMed          Journal:  Rev Epidemiol Sante Publique        ISSN: 0398-7620            Impact factor:   1.019


  15 in total

1.  Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening.

Authors:  Maria Loane; Joan K Morris; Marie-Claude Addor; Larraitz Arriola; Judith Budd; Berenice Doray; Ester Garne; Miriam Gatt; Martin Haeusler; Babak Khoshnood; Kari Klungsøyr Melve; Anna Latos-Bielenska; Bob McDonnell; Carmel Mullaney; Mary O'Mahony; Annette Queisser-Wahrendorf; Judith Rankin; Anke Rissmann; Catherine Rounding; Joaquin Salvador; David Tucker; Diana Wellesley; Lyubov Yevtushok; Helen Dolk
Journal:  Eur J Hum Genet       Date:  2012-06-20       Impact factor: 4.246

2.  Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA.

Authors:  Dagmar Tapon
Journal:  J Genet Couns       Date:  2009-11-03       Impact factor: 2.537

3.  The prevalence of live birth Down syndrome in the region of Primorsko-goranska County in Croatia, 1996-2005: the impact of screening and amniocentesis.

Authors:  Bojana Brajenović-Milić; Igor Prpić; Oleg Petrović; Smiljana Ristić; Gordana Brumini; Miljenko Kapović
Journal:  Matern Child Health J       Date:  2007-08-22

4.  Lithium rescues synaptic plasticity and memory in Down syndrome mice.

Authors:  Andrea Contestabile; Barbara Greco; Diego Ghezzi; Valter Tucci; Fabio Benfenati; Laura Gasparini
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 5.  When half is not enough: gene expression and dosage in the 22q11 deletion syndrome.

Authors:  D W Meechan; T M Maynard; D Gopalakrishna; Y Wu; A S LaMantia
Journal:  Gene Expr       Date:  2007

Review 6.  Down syndrome.

Authors:  Stylianos E Antonarakis; Brian G Skotko; Michael S Rafii; Andre Strydom; Sarah E Pape; Diana W Bianchi; Stephanie L Sherman; Roger H Reeves
Journal:  Nat Rev Dis Primers       Date:  2020-02-06       Impact factor: 52.329

7.  Reduced exercise capacity in persons with Down syndrome: cause, effect, and management.

Authors:  Goncalo V Mendonca; Fernando D Pereira; Bo Fernhall
Journal:  Ther Clin Risk Manag       Date:  2010-12-08       Impact factor: 2.423

8.  Prenatal treatment prevents learning deficit in Down syndrome model.

Authors:  Maddalena Incerti; Kari Horowitz; Robin Roberson; Daniel Abebe; Laura Toso; Madeline Caballero; Catherine Y Spong
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

9.  Maternal age and birth defects after the use of assisted reproductive technology in Japan, 2004-2010.

Authors:  Syuichi Ooki
Journal:  Int J Womens Health       Date:  2013-02-18

10.  Prevention of developmental delays in a Down syndrome mouse model.

Authors:  Laura Toso; Irene Cameroni; Robin Roberson; Daniel Abebe; Stephanie Bissell; Catherine Y Spong
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.